The insightful webinar explored innovative strategies for enhancing drug development efficiency using predictive in vitro and ex vivo models. This session took a deep dive into the latest methodologies that bridge the gap between laboratory research and clinical applications, accelerating the drug development process.
Discover how the approach developed by the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) in Hannover, Germany, streamlines drug development by offering faster, cost-effective, and predictive methods for developing new inhalable therapeutics.
Key highlights included:
Dr. Katharina Schwarz (f) leads the department “Inhalation and Aerosol Sciences” at the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) in Hannover, Germany.
She is an expert at the interface between aerosol/inhalation research, respiratory pharmacokinetics, toxicology/physiology, and inhalation exposure science with a special focus on particle lung dosimetry and biophysical particle-lung interactions. In her institutional role she is responsible for the aerosol aerosol/inhalation and dosimetry-related/QIVIVE-related aspects in drug development programs as well as toxicological and inhalation exposure studies including GLP/GCP-compliance. Customers are major pharmaceutical, chemical and cosmetic companies from Europe and US as well regulatory authorities.
The expoCube provides a novel ALI (air liquid interface) culture exposure system, integrating with the inExpose system’s existing exposure generators such as the integrated cigarette smoking robot and industry leading e-cigarette extensions.
The expoCube features:
Save time evaluating SCIREQ equipment by having a SCIREQ Application Specialist conduct a custom
literature research. Researchers will receive an email report showing SCIREQ publications relevant to their specific application research area, along with custom equipment recommendations and commentary.
